Profound Medical Corp.

NASDAQ:PROF

Medical - Devices

Healthcare
$6.91 +4.11%

+$0.27 today

Market cap
$253.09M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $3.76High $8.95

Volume 0.08M

Average 0.12M

PROF Operating Cash Flow

Cash generated by the company's core business operations during the period.

Profound Medical Corp.NASDAQ: PROF

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow grows, but more slowly than its trailing trend

Q1 FY2026 operating cash flow of $8.58M (cash outflow) rose 3.6% year over year, behind the +43.8% change in trailing-twelve-month operating cash flow. Sequentially, it rose 28.9% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Operating cash flow amounted to 237.3% of revenue in FY2025, up 6.7 pp from a year earlier.
  • Operating cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.6% toward the trailing-twelve-month pace of +43.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.58M+28.9% QoQ
Last fiscal yearDec 2025
-$38.88M+65.8% YoY
LTMMar 2026
-$38.79M+43.8% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.6%——
1 year+65.8%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(38.88M) USD
Year-over-year change
-65.8%

Operating Cash Flow vs competitors

How PROF compares with its peers on the latest reported figures

  • PROF's LTM Mar 2026 operating cash flow of $38.79M is the 4th largest of the 11 companies compared; the peer median is $26.07M.
  • Its year-over-year change of +43.8% is the 3rd highest of 10, against a peer median of -10.5%.
  • Operating cash flow amounts to 205.6% of revenue for PROF, versus a peer median of 65.9%.
PROF Competitors Peer median
Operating Cash Flow for PROF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CATXPerspective Therapeutics, Inc.LTM Mar 2026$92.37M +71.9%+89.2%14946.6%
AVRAnteris Technologies Global Corp.LTM Mar 2026$84.99M +26.5%+38.3%4591.8%
NNOXNano-X Imaging Ltd.LTM Dec 2025$43.17M +18.0%-2.0%331.6%
PROFProfound Medical Corp.LTM Mar 2026$38.79M +43.8%+14.6%205.6%
PREPrenetics Global LimitedLTM Mar 2026$33.94M ——29.8%
MXCTMaxCyte, Inc.LTM Mar 2026$28.17M -10.5%+32.5%87.2%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$23.97M -30.6%-7.4%810.2%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$19.99M -42.0%-17.7%44.5%
STIMNeuronetics, Inc.LTM Mar 2026$12.8M -64.4%-12.8%8.4%
LNSRLENSAR, Inc.LTM Mar 2026$12.16M +211.4%-0.1%21.1%
OWLTOwlet, Inc.LTM Mar 2026$9.87M -28.4%-49.0%9.2%
Peer median (excluding PROF) $26.07M-10.5%-2.0%65.9%

Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.7M)(28.67M)(28.32M)(27.82M)(42.57M)
Depreciation & Amortization1.88M1.6M929K936K569.8K
Deferred Income Tax00000
Stock-Based Compensation7.21M4.24M3.42M2.58M5.49M
Change in Working Capital(877K)(5.63M)540K591K(1.74M)
Accounts Receivables2M(1.42M)(956K)186K(175.01K)
Inventory(2.49M)(1.86M)353K656K(2.87M)
Accounts Payables(356K)(566K)1.35M815K384.62K
Other Working Capital(26K)(1.78M)(211K)(1.07M)918.81K
Other Non-Cash Items132K2.66M828K255K(622.65K)
Operating Cash Flow(22.36M)(25.8M)(22.61M)(23.45M)(38.88M)
Capital Expenditures(593K)000(179.08K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(561K)00091.63K
Investing Cash Flow(593K)000(246.24K)
Debt Repayment(386K)6.92M(912K)(2.56M)(1.33M)
Common Stock Issued00062.11M43.19M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.33M114K2.67M(4.85M)0
Financing Cash Flow5.95M7.03M1.76M54.7M41.86M
Effect of Forex Changes244K(1.87M)549K(2.54M)2M
Net Change in Cash(16.76M)(20.64M)(20.3M)28.7M4.73M
Free Cash Flow(22.95M)(25.8M)(22.61M)(23.45M)(39.05M)

Profound Medical Corp.

NASDAQ:PROF

Intrinsic Alpha fair value

Locked

Current Price

$6.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.